Skip to content

Efficacy and safety of autologous conditioned serum (ACS/Orthokine®) compared with Triamcinolone in the treatment of symptomatic hip osteoarthritis.

Efficacy and safety of autologous conditioned serum (ACS/Orthokine®) compared with Triamcinolone in the treatment of symptomatic hip osteoarthritis. A double-blinded, randomised, controlled, parallel group trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN16719506
Enrollment
130
Registered
2010-03-08
Start date
2010-03-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of the hip Musculoskeletal Diseases Coxarthrosis

Interventions

Study of ultrasound-guided intra-articular injection regimens in the treatment of symptomatic hip osteoarthritis. Treatment with ACS / Orhtokin® will be given 3 times as a 2ml intraarticular injection

Sponsors

Orthogen AG (Germany)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age: over 30 years old 2. Chronic hip osteoarthritic (OA) pain for at least 3 months measured according to American College of Rheumatology (ACR) criteria (Altman, Asch, et al. 1986) 3. X-ray signs of uni- or bi-lateral osteoarthritis of the hip joint (Kellgren 2 or 3; Ravaud & Dougados 1997) 4. Signed written informed consent 5. At least pain grade 4 (measured on a numeric rating scale 0-10)

Exclusion criteria

Exclusion criteria: 1. Pathologies: 1.1. Systemic disease of the musculoskeletal system 1.2. Bone cancer, metastasis or tumour-like lesions in the immediate proximity to the treated joint 1.3. Fracture in the last 3 months 1.4. Acute bacterial infection of the hip to be treated 1.5. Conditions, internal or oncological, which impair the patient?s general fitness (performance status [PS] >2; New York Heart Association [NYHA] >II) 1.6. Blood clotting disorders 1.7. Osteonecrosis of the hip to be treated 2. Treatment: 2.1. Treatment of the affected hip due to osteoarthritis with one of the two study medications in the last 6 months 2.2. Present psychiatric disease requiring therapy 2.3. Ongoing corticoid or non-steroidal anti-inflammatory drug (NSAID) therapy due to other diseases 3. Other: 3.1. Operation on the affected hip within the last 3 months 3.2. Pregnant or breast-feeding patients 3.3. Drug dependency (alcohol, analgesics, opiates, etc.) 3.4. Lack of mental ability to understand the study procedures due to lack of optimal communication capacity (knowledge of the language, dementia, lack of time)

Design outcomes

Primary

MeasureTime frame
1. Mean changes from baseline in the global Western Ontario MacMaster Universities Osteoarthritis Index (WOMAC) score 2. Changes in weight-bearing pain using a numeric rating scale (NRS) All questionnaires will be filled out as a baseline score before the visit, right after the last of three injections, after 3 months and after 6 months.

Secondary

MeasureTime frame
1. Success of therapies measured according to the changes from baseline in the different health-related quality-of-life profiles 1.1. SF-12 1.2. Harris Hip Score 1.3. EuroCol-5d 2. The number of adverse events and serious adverse events wil be used to compare the safety profile of the two treatments groups. All questionnaires will be filled out as a baseline score before the visit, right after the last of three injections, after 3 months and after 6 months.

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026